Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
To provide access to palbociclib to post-menopausal patients with hormone receptor-positive \[HR(+)\], HER2-negative \[HER2(-)\] ABC who are deemed appropriate for letrozole therapy.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Post-menopausal women (\>=18 years of age) with proven diagnosis of advanced carcinoma of the breast (ER(+) and/or PgR(+) and HER2(-)) who are appropriate for letrozole therapy (in the first-line advanced/metastatic disease setting).
Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
Adequate bone marrow, liver, and renal function.
You may not be if
Prior treatment with any CDK inhibitor .
QTc \>480 msec; history of QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes.
High cardiovascular risk, including, but not limited to myocardial infarction, severe/unstable angina, severe cardiac dysrhythmias, and symptomatic pulmonary embolism in the past 6 months of enrollment.
Clareo Health | Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer
